



**Professor Tony Burgess (AC FAA FTSE) Medal
A plenary on the eve of the Post-doc Symposium
Thursday 8 September, Lecture Theatre B**

Background:

Professor Tony Burgess was one of Australia's top cancer researchers, former Director of the Ludwig Institute for Cancer Research in Melbourne, Professor of Surgery at the Royal Melbourne Hospital, University of Melbourne and Laboratory Head at WEHI. He has an illustrious research history with over 300 publications to his name and has given numerous key-note speeches at Institutes and conferences around the world. He discovered the haemopoietic growth factor G-CSF and was part of the team which cloned murine GM-CSF. Much of his research involved the study of epithelial cancers and he was a leader of the team which solved the 3D-structures of the EGFR and HER2 extra-cellular domains. Professor Burgess was also a strong force in the advancement of cancer management and research, having been involved in at least thirty scientific committees, boards and funds. In 1998 he was appointed a Companion of General Division of the Order of Australia (AC) for his outstanding services to science and medicine, especially in the field of cancer research^{1,2}.

The Professor Tony Burgess Medal:

The Professor Tony Burgess Medal has been established to honour the significant contribution of Professor Burgess as a founding member of the VCCC Alliance Board, including the visionary role he played in bringing the integrated model of comprehensive cancer care Victoria to establish the VCCC Alliance. This is a competitive opportunity: the successful recipient will deliver a 40 – 60-minute **plenary address on the eve of the VCCC Alliance Postdoctoral Symposium and be awarded a \$5000 prize.**

The prize is available to early- to mid-stage career researchers, including laboratory group leaders (5 – 15 years post PhD, or equivalent as per the Australian Qualifications Framework Level 10 descriptor), who is currently working within a [VCCC Alliance member organisation](#), or partner¹

The plenary address will showcase the successful applicant's innovative program of cancer focussed research, highlighting collaboration as a key priority.

What will be assessed?

When awarding the prize, the selection committee will consider the strength of the entire application including the CV and assessment criteria

Potential Impact: Innovation, Creativity and Significance ~35%

- Does the program of work showcase innovative information, or present a new area of work?
- Is the work original?
- Is the application written clearly and organized well?
- Is the significance of the work clearly stated?
- Is there clear potential for translation?

¹ VCCC Alliance members: The Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, University of Melbourne, The Royal Women's Hospital, The Royal Children's Hospital, Western Health, St Vincent's Hospital, Austin Health, The Murdoch Children's Research Institute, Walter and Eliza Hall Institute
VCCC Alliance partners: The Olivia Newton-John Cancer Research Institute, St Vincent's Institute



Collaborative Approach: Alignment with VCCC Alliance priority of collaboration ~30%

- Is the program of work cancer focused?
- Does the program of work demonstrate a collaborative, integrated and comprehensive approach?
- Does the program of work involve local, national or international collaborators?
- Does the program of work identify synergies and leverage existing strengths across Alliance member organisations?

National and International Recognition: Including research quality and capability ~20%

- Does the program of work have clearly stated aim(s) and outcome(s)?
- Are the methods well-designed/appropriate to the question(s) addressed, and interim conclusions justified in relation to the data and/or analyses/description?
- Strength of the applicant's CV (relative to opportunity) including publications

Inclusion: Including alignment with VCCC Alliance values of “for all” and “patient centered” ~15%

- Has the program of work involved consumers?
- Does the program of work pursue equitable access to cancer care and outcomes?

Eligibility requirements

- Must be an early- to mid-career researcher, including laboratory group leaders (5 – 15 years post PhD, or equivalent as per the Australian Qualifications Framework Level 10 descriptor) with a VCCC Alliance member or partner².

The committee will **only** consider applicants who:

- satisfy **all** of the eligibility requirements noted above, **and**
- submit a **complete** application by the closing date – **11.59pm (AEST) Thursday 21 July 2022.**
- retrospective applications will not be considered

Application

The **complete** application will consist of the following:

1. **Completed application form**
2. **Curriculum Vitae**
 - Should include the following sections: 1-page maximum, with current and prior positions (last 5 years), positions of responsibility (last 5 years), top ten publications (last 10 years) and a 100-word statement of impact of the applicant's research or work.

For queries please contact Beverly Brigham beverly.brigham@unimelb.edu.au.

¹ VCCC Alliance members: The Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, University of Melbourne, The Royal Women's Hospital, The Royal Children's Hospital, Western Health, St Vincent's Hospital, Austin Health, The Murdoch Children's Research Institute, Walter and Eliza Hall Institute
VCCC Alliance partners: The Olivia Newton-John Cancer Research Institute, St Vincent's Institute